Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. The company develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, cardiovascular diseases, genetic disorders, and others. Its product candidates include SG295 and SG242 that target CD19+ cancer cells, including non-Hodgkin Lymphoma, chronic lymphocytic leukemia, and acute lymphoblastic leukemia; SG221 and SG239 for the …
Over the last 12 months, insiders at Sana Biotechnology, Inc. have bought $18M and sold $1.43M worth of Sana Biotechnology, Inc. stock.
On average, over the past 5 years, insiders at Sana Biotechnology, Inc. have bought $6.23M and sold $2.85M worth of stock each year.
Highest buying activity among insiders over the last 12 months: NELSEN ROBERT () — $42M. CRANDELL KEITH (10 percent owner) — $30M. ARCH Venture Fund X, L.P. (10 percent owner) — $6M.
The last purchase of 1,090,909 shares for transaction amount of $6M was made by NELSEN ROBERT () on 2024‑02‑08.
2024-09-25 | Sale | director | 150,000 0.0641% | $3.89 | $583,170 | +9.83% | ||
2024-09-24 | Sale | director | 150,000 0.0673% | $4.08 | $612,570 | +4.56% | ||
2024-03-08 | Sale | director | 25,000 0.0113% | $9.45 | $236,300 | -38.99% | ||
2024-02-08 | 1.09M 0.5382% | $5.50 | $6M | -0.81% | ||||
2024-02-08 | 10 percent owner | 1.09M 0.5382% | $5.50 | $6M | -0.81% | |||
2024-02-08 | 10 percent owner | 1.09M 0.5382% | $5.50 | $6M | -0.81% | |||
2023-12-15 | Sale | EVP, Chief Business Officer | 75,000 0.0378% | $4.00 | $300,098 | +46.07% | ||
2023-06-07 | Sale | 10 percent owner | 200,000 0.1051% | $6.24 | $1.25M | -6.12% | ||
2023-06-06 | Sale | 10 percent owner | 203,758 0.106% | $6.31 | $1.28M | -8.04% | ||
2023-05-26 | Sale | 10 percent owner | 82,000 0.0425% | $6.23 | $510,573 | -7.64% | ||
2023-05-25 | Sale | 10 percent owner | 115,372 0.0614% | $6.35 | $732,866 | -6.89% | ||
2023-05-24 | Sale | 10 percent owner | 347,870 0.1843% | $6.57 | $2.28M | -10.19% | ||
2022-03-21 | 28,000 0.016% | $7.30 | $204,400 | -19.10% | ||||
2022-02-18 | Sale | EVP & General Counsel | 333 0.0002% | $6.28 | $2,091 | -5.54% | ||
2021-09-16 | Sale | EVP, Head of Development & CMO | 1,627 0.0009% | $26.00 | $42,302 | -69.16% | ||
2021-09-15 | Sale | EVP, Head of Development & CMO | 58,373 0.0323% | $26.07 | $1.52M | -69.32% | ||
2021-09-10 | Sale | EVP, Chief Business Officer | 1,477 0.0008% | $25.00 | $36,925 | -67.78% | ||
2021-09-09 | Sale | EVP, Chief Business Officer | 64,671 0.0361% | $25.01 | $1.62M | -67.46% | ||
2021-09-03 | Sale | EVP, Chief Business Officer | 700 0.0004% | $25.00 | $17,500 | -67.18% | ||
2021-09-02 | Sale | EVP, Chief Business Officer | 7,958 0.0045% | $25.00 | $198,968 | -66.80% |
CRANDELL KEITH | 10 percent owner | 12446022 5.5745% | $1.65 | 1 | 0 | |
NELSEN ROBERT | 12446022 5.5745% | $1.65 | 1 | 0 | ||
ARCH Venture Fund X, L.P. | 10 percent owner | 12446022 5.5745% | $1.65 | 1 | 0 | |
Yang Patrick Y | director | 149250 0.0668% | $1.65 | 1 | 1 | <0.0001% |
Bilenker Joshua H. | director | 20000 0.009% | $1.65 | 1 | 0 |
Flagship Pioneering | $250.02M | 11.29 | 25M | New | +$250.02M | 16.4 | |
Fidelity Investments | $220.43M | 9.95 | 22.04M | New | +$220.43M | 0.02 | |
The Vanguard Group | $121.55M | 5.49 | 12.16M | +24.07% | +$23.58M | <0.01 | |
Baillie Gifford Co | $106.56M | 4.81 | 10.66M | New | +$106.56M | 0.08 | |
Canada Pension Plan Investment Board | $101.75M | 4.59 | 10.18M | 0% | +$0 | 0.1 |